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We have studied the role of MPL mutations in early and leukaemic phase MPN, focusing on the prevalence of mutations in exon 9, the role of MPL and additional mutations in leukaemic transformation and mechanisms by which the wild-type MPL allele is lost. Cell fractionation and progenitor colony assays were performed as described (15) . TET2 (all coding exons) were assessed by direct sequencing. MPL copy number was assessed by real-time PCR using control regions on 13q and 9p.
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Expression of the AML-associated MPL exon 9 T487A allele in mouse bone marrow cells Table 1 ). No mutations were detected.
These data indicate that MPL exon 9 mutations occur rarely, if at all, in human MPN.
Progression to acute leukaemia is observed in a proportion of patients with a JAK2-mutant, MPL-mutant or mutation negative MPN, and in ET the presence or absence of an MPL mutation does not appear to modulate this risk (4) . To investigate the role of MPL mutations in leukaemic transformation, we studied three patients with AML following an MPL W515L-positive MPN (Table 1 ). All three patients were negative for the JAK2 V617F mutation. In patients 1 and 2, bone marrow studies performed at AML progression showed granulocytic hyperplasia, dysplastic megakaryocytes, reticulin fibrosis 3 (graded on a 0-4 scale) and clusters of CD34+ cells, in keeping with the AML subtype 'acute panmyelosis with fibrosis' (18) ( Figure 1A ). In patient 3, AML was diagnosed by >95% blast cells in the peripheral blood. Patients 1 and 3 had received hydroxycarbamide but patient 2 had not received cytoreductive therapy. As patients with a JAK2 V617F-positive MPN may develop leukaemia that lacks the JAK2 mutation (13-15), leukemia MPL mutation status was determined using purified blasts, free from contamination by the preceding MPN. In patient 1, initially diagnosed with ET, leukaemic blasts were heterozygous for the MPL W515L mutation, whereas in patients 2 and 3, with preceding PMF and post-ET myelofibrosis respectively, only the mutant MPL allele was detected ( Figure 1B ). The absence of wildtype allele in patients 2 and 3 might reflect acquisition of a second mutation, deletion of the wild-type allele or mitotic recombination.
To distinguish between these possibilities, we studied W515L-homozygous leukaemic blasts from patients 2 and 3 together with granulocytes from a W515L-positive JAK2 V617F-negative PMF patient (patient 4) with a mutant allele proportion of >0.9. In all 3
patients, informative SNPs (genotyped by direct sequencing) at both the telomeric end of the MPL locus and 39Mb distal (close to the 1p telomere) showed loss of heterozygosity in leukaemic blasts (patients 2 & 3) or granulocytes (patient 4) (data not shown), excluding acquisition of a second MPL mutation. To distinguish deletion of the wild-type allele from mitotic recombination, MPL copy number was assessed by real-time PCR, which demonstrated two copies of MPL in all cases ( Figure 1C ). These findings demonstrate that homozygosity for an acquired MPL W515L mutation had arisen by mitotic recombination in these three patients, confirming previous studies in which acquired uniparental disomy affecting the MPL locus had been detected by SNP array technology (10) (11) (12) Mutations were identified in TP53 and TET2 in patient 1 but no additional lesions were found in patients 2 and 3. In patient 1, the TET2 mutation was predominant in bone marrow cells obtained 3 years prior to leukemic transformation, whereas the MPL mutation was present at a relatively low level (Figure 2A ).
Sequencing is not highly quantitative, but the magnitude of the observed difference suggests that the TET2 mutation preceded acquisition of the MPL mutation. Erythroid and granulocyte-macrophage colonies (n=41 and n=21 respectively), confirmed by cytological analysis, all harboured both MPL and TET2 mutations, demonstrating that the mutations arose within the same clone. In addition, 13 of 62 colonies harbored mutations in TP53.
Remarkably, a total of four different TP53 mutations were identified, all of which are recurrent, functionally-significant cancer-associated alleles (19) . Progression to acute leukemia was associated with loss of wild-type TP53 in one subclone (Figure 2A ).
Detection of TP53 mutations within erythroid and granulocyte-macrophage colonies
indicates that terminal differentiation may proceed in the presence of mutant p53 where the wild-type allele is retained. Furthermore, the presence of multiple p53-mutant clones, all involving C:G-to-T:A transitions (Figure 2A) , implies a mutator-phenotype prior to the development of an AML-associated differentiation block. One possible mechanism invokes a mutagenic effect of mutant MPL, TET2 or other unidentified genes, as reported in models of oncogenic ERBB2 and BCR-ABL1 which resulted in a bias towards transversion or transition mutations respectively (20, 21) . In this patient, no other acquired synonymous or non-synonymous mutations were identified in 11.5Kb of DNA sequence from leukemic blasts, although the mutation prevalence in solid tumours (1 mutation every 10 5 -10 6 bases) suggests that a genome-wide approach would be necessary to elucidate the true 7 mutation frequency. In addition, it is possible that alterations of MPL, TET2 or unidentified gene(s) within the parental clone impart a strong selective pressure for the acquisition of TP53 mutations. Alternatively, diverse clones may arise following exposure to an exogenous agent. Hydroxycarbamide (received by this patient) has been linked to abnormalities of 17p (which harbours the TP53 locus) (22, 23) , although a specific mutation signature has not been reported.
Taken together, our data demonstrate the parallel expansion of genetically distinct but phylogenetically-related clones prior to leukemic transformation ( Figure 2B ). Of note, clonal diversity (assessed by loss of heterozygosity and TP53/CDKN2A mutation) in patients with Barrett's oesophagus has been associated with an increased risk of progression to adenocarcinoma (24) , suggesting that in this disease expansion of competing clones may also presage progression to a fully malignant phenotype. 
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